All posts tagged "Biohaven"

FDA to Decide on Biohaven’s Controversial Drug for SCA

The Food and Drug Administration (FDA) is set to announce its decision in mid-November 2023 regarding Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia (SCA), a rare neurodegenerative...